Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • News & Featured Stories
  • Media
  • Careers
  • Contact Us
  • Our Science

    Sub Menu 1

    • Pfizer in the UK
      • Our History
      • Pharmaceutical Sciences
      • Devices Centre of Excellence
      • Global Regulatory Affairs
      • Material Characterisation Team
      • Anti-Counterfeit Laboratory
    • Our Therapy Areas
      • Anti-Infectives
      • Inflammation and Immunology
      • Internal Medicine
      • Oncology
      • Rare Disease
      • Vaccines

    Sub Menu 2

    • Developing New Medicines
      • Clinical Trials
      • Pipeline
    • Research partnerships
      • ADDoPT
      • Innovative Target Exploration Network (ITEN)
      • INSPIRE Programme
      • Medical Research Council Collaboration
      • The Stratified Medicine Programme
      • Partnership with Regeneron for UK Biobank exome sequencing
    • Breakthroughs that change patients’ lives
    Hot Topic

    Re-shaping Cancer

    Re-shaping cancer
  • Products

    Sub Menu 4

    • Prescription medicines

    Sub Menu 5

    • Safety of Medicines
      • Medicines Regulation
      • Reporting Side Effects
      • Counterfeit Medicines
    Hot Topic

    Vaccines partnerships

    Vaccines partnerships
  • Responsibility

    Sub Menu 7

    • Transparency
      • HCP & HCO Annual Disclosure Reports
      • Healthcare Organisation Grants
      • Research and Development Funding
      • Patient Organisation Funding and Support
    • Codes of Conduct
      • Gender Pay Gap Report
      • Section 172 Statements
      • Pfizer UK Modern Slavery Statement
      • Pfizer UK Tax Strategy

    Sub Menu 8

    • Environmental Sustainability
      • Climate Action
      • Global Actions
      • Our Partnerships & Commitments
      • Sustainable Medicines
      • UK Actions
    • Insurance Details
    • Animal Welfare
    Hot Topic

    Putting Patients First

    Putting Patients First
  • UK Society

    Sub Menu 10

    • Social Investment
      • Volunteering and Fundraising
      • Medicines Donations
    • Raising Public Awareness
      • Change the Course
      • Pfizer Sponsors Science Museum Group's 'Cancer Revolution' Exhibition
      • Pfizer Sponsors the Superhero Series
      • Pfizer sponsors Science Museum exhibition 'Superbugs'
      • Pfizer at the British Science Festival
      • Turning Heads at Westminster

    Sub Menu 11

    • Science Education
      • Developing Science Talent
      • 'Superbugs Join The Fight' School Programme
      • Online Learning
        • Student Education Area
        • Teacher Resources
      • Community Lab
      • Career Talks
      • Lab in a Box
    • Pfizer Worldwide
      • Global Health Fellows
      • Global Aid and Emergency Relief
      • International Trachoma Initiative
    Hot Topic

    'Superbugs' Competition Winners

    Superbugs Winners
  • UK Health System

    Sub Menu 16

    • Working with the NHS and other Healthcare Organisations
      • Collaborative Working
        • Collaborative Working Project between Lloyds Pharmacy and Pfizer Vaccines
        • Joint Working
      • Donations and Grants
        • Independent Medical Grants and Donations
        • Donations of Goods, Services and Benefit in Kind
        • Grants
        • Donations and Grants Enquiry Form
    • Working with Healthcare Professionals
      • FAQs: Working with Healthcare Professionals
      • Pharmacy
      • Healthcare Professionals Congress Sponsorship

    Sub Menu 17

    • Working with Patient Organisations
      • Patient Involvement in Research and Development
      • Our ongoing partnership with the UK Sepsis Trust
      • Partnering with the NIHR and young people on clinical research
    • Pfizer Healthcare Hub
      • Pfizer Healthcare Hub: 2018
      • Pfizer Healthcare Hub: 2017
      • Connect with the Hub
    Hot topic

    Osteoarthritis

    Osteoarthritis
  • News & Featured Stories
  • Media
  • Careers

    Carrers

    • Search Current Vacancies
    • Apprenticeships
      • Apprenticeship Vacancies
    • Undergraduate Placements
      • Undergraduate Vacancies
    • Meet our people
    • UK Top Employer
  • Contact Us
  • Footer links

    Footer mobile menu

    • Footer Menu
    • Footer menu
      • Contact Us
      • Cookie Policy
      • Terms of Use
      • Privacy Policy
      • Sitemap
    • Footer social item
      • Facebook
      • Twitter
      • Instagram
      • YouTube

Antimicrobial Resistance Explained

Antimicrobial Resistance Explained
News & Featured Stories/ Antimicrobial Resistance Explained
28/03/2022

You may have heard about ‘AMR’ on the TV or read about it in the paper – but what is AMR and what can be done about it? We’ve taken some of the most common questions about this important health issue and answered them below.

So, what exactly is AMR?

AMR – or antimicrobial resistance – is when a microbe is able to survive exposure to a medicine that would normally kill it or stop its growth. These medicines are called antimicrobials and there are many different types, though antibiotics are probably the most well-known.

Microbes are tiny living things that are often harmless, however some can cause diseases. There are four main types of microbe which can cause a range of infections:

  • Bacteria – e.g. Salmonella
  • Virus – e.g. HIV
  • Fungus – e.g. Athlete’s foot
  • Protozoa – e.g. Malaria

Microbes that survive treatment with antimicrobial medicines can grow and spread, leading to the emergence of ‘superbugs’ that are difficult, or sometimes impossible to treat. A well-known example of a superbug is MRSA: methicillin-resistant Staphylococcus aureus (methicillin being an antibiotic, and Staphylococcus aureus being a bacterium that is resistant to it).

MRSA infections usually occur in hospitals1 and can sometimes spread throughout the whole body, leading to severe disease and sepsis – a life-threatening reaction to an infection.2 Another example is Candida auris, an emerging multidrug-resistant fungus that is spreading rapidly worldwide and mainly affects critically ill patients in intensive care units.3

Why can some microbes survive exposure to medicines designed to kill them?

Microbes, such as bacteria, have been around for billions of years and are constantly evolving. They survive by sensing their surroundings and adapting when conditions aren’t ideal – for example in extreme heat, extreme acidity or exposure to harmful agents.4 So, when microbes in your body are exposed to a medicine designed to kill them, they can mutate in an attempt to survive. 

Whilst many of these mutations won’t be successful, some can help the microbe to survive. These resistant microbes are then free to multiply and spread to others – causing infections which are drug-resistant.

If AMR has been happening for a long time, why is there an ‘AMR crisis’ now?

Whilst AMR has been occurring naturally for a long time, human behaviour is making it worse. Today, drug-resistant infections are one of the biggest health challenges facing society.5 Some of the main drivers are:

1Misuse and overuse of antimicrobials (e.g. antibiotics)
2Lack of access to clean water, sanitation and hygiene for both humans and animals
3Poor infection control in healthcare facilities and farms
4Lack of access to medicines, vaccines and diagnostics
5Lack of awareness and knowledge about AMR and how to take action against it

Each of us has a vital role in helping to stop the spread of drug-resistant infections. Precautions that were recommended during the pandemic like washing your hands regularly can have a real impact, as well as ensuring vaccinations are up to date and using antimicrobials only as prescribed by your doctor.

Why can’t we just make more antimicrobials to stop AMR?

Making new medicines is just one part of the solution. Researchers are hard at work developing new antimicrobials, however this alone isn’t enough to stop AMR. Over time, microbes will continue to evolve and become resistant to the new medicines too.

We can't stop microbes evolving and becoming resistant. But we can change our relationship with antimicrobials and recognise AMR as a health issue we must live with and work hard to keep at bay. An important part of this is reducing the inappropriate use of the antimicrobials we already have to keep them working for longer. 

Why should we care?

AMR poses a real risk to our health and is already having a major impact around the world. More than 1.2 million people died worldwide in 2019 from infections caused by bacteria resistant to antibiotics.6 This is more than the annual death toll from malaria or AIDS.7,8

AMR also has a significant impact on healthcare systems and can result in longer hospital stays, ward closures and cancelled procedures.9 In fact, the annual cost of AMR to the NHS has been estimated as £180 million per year.10

Without effective action on AMR, the number of people who die from infections will increase. Everyday medical procedures like caesarean sections, hip replacements, chemotherapy and organ transplants will become very high risk, as any infections picked up during these procedures won’t be treatable.

We need to maintain a global collaborative response before it’s too late. We’ve seen what can be accomplished when industry, government, our healthcare system and academia come together to take urgent action on health threats, and the same must be done for AMR.

 

If you would like to know more about how you can help to tackle the spread of AMR, read our Change the Course report.

References

  1. NHS. Conditions, MRSA. Last accessed: March 2022. 
  2. Sepsis Alliance. MRSA. Last accessed: March 2022. 
  3. Ademe, M., & Girma, F., 2020. Candida auris: From Multidrug Resistance to Pan-Resistant Strains. Infection and drug resistance, 13, 1287–1294. Last accessed: March 2022. 
  4. Gao, H., Weitao, T., He, Q., 2011. Coping with the Environment: How Microbes Survive Environmental Challenges. International Journal of Microbiology. Last accessed: March 2022.
  5. World Health Organization. Antimicrobial resistance. Last accessed: March 2022.
  6. Antimicrobial Resistance Collaborators: Murray C, Ikuta KS, Sharara F et al. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. Volume 399, issue 10325, p629-655. Last accessed: March 2022
  7. World Health Organization. Malaria. Last accessed: March 2022.
  8. UNAIDS. Global HIV & AIDS statistics – Fact sheet. Last accessed: March 2022. 
  9. Dadgostar, P., 2019. Antimicrobial Resistance: Implications and Costs. Infection and Drug Resistance. Volume 23, p3902-3910 Last accessed: March 2022
  10. House of Commons Health and Social Care Committee. 2018. Oral evidence: Antimicrobial resistance, HC 962. Last accessed: March 2022. 
     

 

PP-UNP-GBR-0208 / March 2022

Related Hot Topics
What is a Variant
What is a Variant?
Patients at heart of clinical trials
Why putting patients at the heart of Pfizer UK’s clinical trials continues to…
Infection Management Coalition Paper
Cross-Industry Coalition Tackling ‘Hidden Pandemic’ of Antibiotic Resistant…
Maternal Immunisation
Protecting Babies from Inside the Womb
Protease Inhibitor
How Does a Protease Inhibitor Work?
Gene Sequencing
How Gene Sequencing Inaugurated a New Era in Modern Medicine
Re-shaping cancer
Re-shaping Cancer - Breakthroughs that change patients' lives
How Do Viruses Make Us Sick?
How Do Viruses Make Us Sick?
Tags
Science / R&D
Anti-Infectives

Footer

  • Contact Us
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Sitemap

Footer aside

  • Footer Aside
    • Facebook
    • Twitter
    • Instagram
    • YouTube

Copyright © 2017-2022 Pfizer Limited. PP-PFE-GBR-4248 / Nov 2021. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427